A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Evaluate the Effects of Niaspan on Reverse Cholesterol Transport in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 12 Nov 2013
At a glance
- Drugs Niacin (Primary)
- Indications Atherosclerosis; Lipid metabolism disorders
- Focus Pharmacodynamics
- Sponsors Merck & Co
- 08 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Sep 2010 Planned end date changed from 1 Jul 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
- 25 Feb 2010 New trial record